We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax.
- Authors
Wallace, D. S.; Rowland, C.; Hill, B. T.; Baran, A. M.; Casulo, C.; Reagan, P. M.; Winter, A.; Karmali, R.; Winter, J. N.; Gordon, L. I.; Bui, A.; Sportelli, P.; Weiss, M. S.; Miskin, H. P.; Friedberg, J. W.; Ma, S.; Barr, P. M.
- Abstract
Venetoclax based combination therapy does not overcome poor outcomes in BTKi-refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax Cellular therapies should be prioritized for these patients for whom there is a critical ongoing need for novel treatment options. B Introduction: b Novel agents such as the Bruton's tyrosine kinase inhibitors (BTKi) have improved care for patients with mantle cell lymphoma (MCL), yet progression during BTKi is associated with poor outcomes.
- Subjects
MANTLE cell lymphoma; BRUTON tyrosine kinase; VENETOCLAX
- Publication
Hematological Oncology, 2023, Vol 41, p484
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_356